Clinical Trial Update: A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase II randomized, double-blind, placebo-controlled study assessing the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-708163

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED